Abstracts tagged "rheumatoid arthritis"

Abstract Number: 988 • 2019 ACR/ARP Annual Meeting
Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis
Bradley Hooker¹, Xiaomeng Zhang ², Todd Cole ², Ann Tovcimak ², Shaughn Bryant ³, Lucy Phillips ³, David Blanchard ², Dustin Wooten ², Qi Guo ², Melanie Ruzek ³, Adrian Hobson ³, Michael McPherson ³, Robert Stoffel ³, Wendy Waegell ³ and Yanping Luo ², ¹AbbVie, North Chicago, IL, ²AbbVie, North Chicago, ³AbbVie, Worcester
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory joint disease of autoimmune etiology. If insufficiently treated, RA leads to joint damage and irreversible disability. Although there…
Abstract Number: 1401 • 2019 ACR/ARP Annual Meeting
Australian Rheumatoid Arthritis (RA) Biologic Treatment Pathways: An Australian Rheumatology Association Database (ARAD) Analysis
Ashley Fletcher ¹, Marissa Lassere², Lyn March ³, Catherine Hill ⁴, Claire Barrett ⁵, Graeme Carroll ⁶ and Rachelle Buchbinder ¹, ¹Cabrini Health/Monash University, Melbourne, Australia, ²St George Hospital, University of New South Wales, Sydney, Australia, ³University of Sydney, Sydney, Australia, ⁴Royal Adelaide Hospital/The University of Adelaide/The Queen Elizabeth Hospital, Adelaide, Australia, ⁵Redcliffe Hospital, University of Queensland, Redcliffe, Australia, ⁶Fiona Stanley Hospital, Perth, Australia
Background/Purpose: To describe current biologic disease-modifying antirheumatic drug (bDMARD) treatment patterns for Australian Rheumatology Association Database (ARAD) participants with Rheumatoid Arthritis (RA) including switching and…
Abstract Number: 2004 • 2019 ACR/ARP Annual Meeting
Protein Profiling and Network Enrichment Analysis in Individuals Before and After the Onset of Rheumatoid Arthritis
Mikael Brink ¹, Anders Lundquist ¹, Andrey Alexeyenko ², Kristina Lejon ¹ and Solbritt Rantapää-Dahlqvist¹, ¹Umeå University, Umeå, Sweden, ²SciLife lab, Stockholm, Sweden
Background/Purpose: Antibodies and up-regulated cytokines and chemokines predate the onset of symptoms of rheumatoid arthritis (RA). The aims with this study was to identify pathways…
Abstract Number: 2381 • 2019 ACR/ARP Annual Meeting
Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Kuan-Hsiang Gary Huang ⁷, Sean Connolly ⁷, Yedid Elbez ⁸, Karissa Lozenski ⁹ and Roy Fleischmann ¹⁰, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Princeton, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) +…
Abstract Number: 504 • 2019 ACR/ARP Annual Meeting
A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis
Kenneth Kalunian¹, Mark Genovese ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, Alena Pechonkina ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, Kurt de Vlam ⁶, David Walker ⁷ and Tsutomu Takeuchi ⁸, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Stanford University, Stanford, CA, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁷Northumbria Healthcare, Northumbria, United Kingdom, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: RA patients who have failed biologic DMARDs represent an unmet medical need. We explored the impact of baseline demographics and clinical characteristics on filgotinib…
Abstract Number: 539 • 2019 ACR/ARP Annual Meeting
A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA
Gerd Burmester¹, Stanley Cohen ², David Chien ³, Vincent Chow ³ and Zhiying Pan ³, ¹Charité—University Medicine Berlin, Berlin, Germany, ²Metroplex Clinical Research Center, Dallas, TX, ³Amgen, Thousand Oaks, CA
Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…
Abstract Number: 989 • 2019 ACR/ARP Annual Meeting
Lineage Tracing of Murine Lymphatic Smooth Muscle Cells to Determine the Role of the Lymphatic System in Inflammatory Arthritis
H. Mark Kenney¹, Richard Bell ² and Edward Schwarz ¹, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Dysfunction of lymphatic vessel contraction has been implicated in inflammatory arthritis progression and arthritic flare in murine models. Previous studies have demonstrated that tumor…
Abstract Number: 1404 • 2019 ACR/ARP Annual Meeting
Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea
Min Jung Kim¹, Anna Shin ², Seonghwan Shin ², You-Jung Ha ³, Yun Jong Lee ⁴, Eun Bong Lee ⁵, Yeong-Wook Song ¹ and Eun Ha Kang ³, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul
Background/Purpose: Limited data are available on whether patients with rheumatoid arthritis (RA) are treated with conventional disease-modifying anti-rheumatic drugs (cDMARDs) according to the current recommendations…
Abstract Number: 2008 • 2019 ACR/ARP Annual Meeting
Histone Lysine Methyltransferase MLL1 Regulates the Expression of Cytokines and Chemokines in Rheumatoid Arthritis Synovial Fibroblasts
Yasuto Araki¹, Keita Okamoto ¹, Yoshimi Aizaki ¹, Hiromi Oda ² and Toshihide Mimura ¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Department of Orthopedic Surgery, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints. The inflammatory process causes the activation of synovial fibroblasts (SFs) and…
Abstract Number: 2387 • 2019 ACR/ARP Annual Meeting
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
isabel Hernandez Rodriguez¹, Zulema Rosales Rosado ¹, pia Lois ¹, Cristina Lajas ¹, Judit Font Urgelles ², Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has changed drastically in the last two decades in strategies and objectives, as well as in therapeutic options, especially…
Abstract Number: 507 • 2019 ACR/ARP Annual Meeting
Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³, Daisuke Kato ³ and Désirée van der Heijde ⁴, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…
Abstract Number: 543 • 2019 ACR/ARP Annual Meeting
Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients
Sergio Duran-Barragan¹, Efrain Chavarria-Avila ¹, Marisol Esesarte-Rodriguez ¹, Rosal Valenzuela-Marrufo ¹, Karla Arrona-Ríos ¹, Jorge Aguilar-Arreola ¹, Oscar Pizano Martínez ¹ and Monica Vazquez-del Mercado ¹, ¹Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Background/Purpose: Different types of cells play pathogenic roles in Rheumatoid Arthritis (RA). The immunogenetics of RA suggests a key role of aberrant pathways of T…
Abstract Number: 991 • 2019 ACR/ARP Annual Meeting
Identification of Citrullinated Peptide Specific T-cells in Humanized Mice Immunized with Citrullinated Peptides
Matthew McElwee¹, Thamotharampillai Dileepan ¹ and Marc Jenkins ¹, ¹University of Minnesota, Minneapolis, MN
Background/Purpose: Seropositive rheumatoid arthritis (RA) is a T-cell mediated disease that is characterized by the presence of antibodies to proteins that have undergone the post-translational…
Abstract Number: 1411 • 2019 ACR/ARP Annual Meeting
Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy
Yushiro Endo¹, Tomohiro Koga ¹, Shin-ya Kawashiri ¹, Ayako Nishino ¹, Momoko Okamoto ¹, Shimpei Morimoto ², Sosuke Tsuji ¹, Ayuko Takatani ¹, Toshimasa Shimizu ¹, Remi Sumiyoshi ¹, Takashi Igawa ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Hideki Nakamura ¹, Tomoki Origuchi ³, Yukitaka Ueki ⁴, Tamami Yoshitama ⁵, Nobutaka Eiraku ⁶, Naoki Matsuoka ⁷, Akitomo Okada ⁸, Keita Fujikawa ⁹, Hiroaki Hamada ¹⁰, Tomomi Tsuru ¹¹, Shuji Nagano ¹², Yojiro Arinobu ¹³, Toshihiko Hidaka ¹⁴, Yoshifumi Tada ¹⁵ and Atsushi Kawakami ¹⁶, ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²Nagasaki University Hospital Clinical Research Centre, Nagasaki, Japan, ³Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁴Sasebo Chuo Hospital Rheumatic and Collagen Disease Center, Sasebo, Japan, ⁵Yoshitama Clinic for Rheumatic Diseases, Kirishima, Japan, ⁶Eiraku Clinic for Rheumatic Diseases, Kagoshima, Japan, ⁷Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ⁸Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁹JCHO Isahaya General Hospital Department of Rheumatology, Isahaya, Japan, ¹⁰Miyazaki University Hospital, Miyazaki, Japan, ¹¹PS clinic, Fukuoka, Japan, ¹²Aso Iizuka Hospital, Iizuka, Japan, ¹³Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Japan, ¹⁴Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, ¹⁵Saga University Hospital, Saga, Japan, ¹⁶Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: Rheumatoid arthritis (RA) occasionally overlaps Sjogren’s syndrome (SS), and RA patients with secondary SS have a higher disease activity of RA and worse joint…
Abstract Number: 2009 • 2019 ACR/ARP Annual Meeting
Biomarkers Identified by Serum Inflammatory Profile Analysis to Predict Biologic Treatment Response in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Nuria Barbarroja ², Carlos Perez-Sanchez ³, Pilar Font ⁴, Alejandro Ibañez-Costa ¹, Maria Luque-Tevar ¹, Alejandra Patiño-Trives ¹, Ivan Arias de la Rosa ⁴, Maria del Carmen Abalos-Aguilera ¹, Rafaela Ortega ¹, Alejandro Escudero ⁵, Laura Pérez-Sanchez ⁶, Jerusalem Calvo-Gutierrez ¹, Rocío Segura-Ruiz ⁷, Carlos Rodriguez Escalera ⁸, Dolores Ruiz-Montesinos ⁹, Carmen Romero Barco ¹⁰, N. Mena-Vazquez ¹¹, Julia Uceda Montañez ¹², Mª Dolores Toledo Coello ¹³, M Angeles Aguirre ¹⁴ and Eduardo Collantes-Estevez ⁴, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁶MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁷Reina Sofia University Hospital/IMIBIC, Córdoba, Spain, ⁸Hospital Universitario de Jaén, Jaen, Spain, ⁹Hospital Virgen Macarena, Sevilla, ¹⁰Hospital Marítimo de Torremolinos, Málaga, Málaga, Spain, ¹¹HU Malaga., Malaga, ¹²Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, ¹³Hospital Universitario de Jerez de la Frontera, Cádiz, Cádiz, Spain, ¹⁴IMIBIC/Reina Sofia Hospital/University of Cordoba,, Córdoba, Spain
Background/Purpose: Biologic disease modifying antirheumatic drugs (b-DMARDs) have revolutionized the management of Rheumatoid Arthritis (RA). Despite this success, a high percentage of the patients undergoing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].